اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,846
تعداد مقالات32,300
تعداد مشاهده مقاله41,387,131
تعداد دریافت فایل اصل مقاله18,562,183
Mousa, Z. S, Abdulamir, A. S. (1400). Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay. سامانه مدیریت نشریات علمی, 77(1), 391-402. doi: 10.22092/ari.2021.356677.1890
Z. S Mousa; A. S Abdulamir. "Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay". سامانه مدیریت نشریات علمی, 77, 1, 1400, 391-402. doi: 10.22092/ari.2021.356677.1890
Mousa, Z. S, Abdulamir, A. S. (1400). 'Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay', سامانه مدیریت نشریات علمی, 77(1), pp. 391-402. doi: 10.22092/ari.2021.356677.1890
Mousa, Z. S, Abdulamir, A. S. Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay. سامانه مدیریت نشریات علمی, 1400; 77(1): 391-402. doi: 10.22092/ari.2021.356677.1890

Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay

Archives of Razi Institute
مقاله 49، دوره 77، شماره 1، فروردین و اردیبهشت 2022، صفحه 391-402    اصل مقاله (501.25 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.356677.1890
نویسندگان
Z. S Mousa* 1؛ A. S Abdulamir2
1Baghdad Veterinary Hospital, Baghdad, Iraq
2Department of Medical Microbiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
چکیده
The establishment of an approach for detecting the anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-receptor-binding domain (RBD) neutralizing antibodies (nAbs) by a safe, easy, and rapid technique without requiring the use of live viruses is essential for facing the coronavirus disease 2019 (COVID-19) pandemic. Depending on competitive enzyme-linked immunosorbent assay (ELISA) methodology, the current study assay was designed to simulate the virus-host interaction using purified SARS-COV-2-RBD from the spike protein and the host cell receptor human angiotensin-converting enzyme 2 protein. The performance of this in-house neutralizing ELISA assay was validated using freshly prepared standards with different known concentrations of the assay. In this regard, a cohort of 50 serum samples from convalescent COVID-19 individuals with different disease severity at different time points post-recovery and a cohort of 50 serum samples from healthy individuals were processed by the in-house developed assay for detecting SARS-CoV-2 nAbs, in comparison with a commercial total anti-SARS-CoV-2 IgG antibody assay as a gold standard. The assay obtained a sensitivity of 88% (95% CI: 75.69-95.47) and a specificity of 92% (95% CI: 80.77- 97.78%). A negative strong correlation was demonstrated in the standard curve between the optical density absorbance and log concentration of the nAbs with a statistical measure of r2 (coefficient of determination) = 0.9539. The SARS-COV-2-RBD neutralizing ELISA assay serves as a high throughput qualitative and quantitative tool that can be applied in most laboratory settings without special biosafety requirements to detect anti-RBD nAbs for seroprevalence, pre-clinical, and clinical evaluation of COVID-19 vaccines efficiency and the rapid selection of convalescent plasma donors for the treatment of COVID-19 patients.
کلیدواژه‌ها
COVID-19؛ nAbs؛ Neutralizing antibodies؛ SARS-COV-2-RBD neutralizing ELISA assay
سایر فایل های مرتبط با مقاله
مراجع
  1. Abebe EC, Dejenie TA, Shiferaw MY, Malik T. The newly emerged COVID-19 disease: a systemic review. Virol J. 2020;17(1):96.
  2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.
  3. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-25.
  4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
  5. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80 e8.
  6. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
  1. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, 3rd, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020;182(2):429-46 e14.
  2. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors. Nature. 2020.
  3. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489-501 e15.
  4. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020;52(6):971-7 e3.
  5. Odak I, Barros-Martins J, Bosnjak B, Stahl K, David S, Wiesner O, et al. Reappearance of effector T cells is associated with recovery from COVID-19. EBioMedicine. 2020;57:102885.
  6. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453-5.
  7. Ozcurumez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M, et al. SARS-CoV-2 antibody testing-questions to be asked. J Allergy Clin Immunol. 2020;146(1):35-43.
  8. Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395(10230):1101-2.
  9. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-8.
  10. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073-8.
  11. Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, et al. Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents. 2020.
  12. LibreTexts C. 12.3: Mass-Mole and Mole-Mass Stoichiometry 2021 [Available from: https://chem.libretexts.org/@go/page/53791.
  13. Origene. ELISA Development Guide 2012 [Available from: https://cdn.origene.com/assets/documents/assays/elisa_luminex_development_guide.pdf.
  14. Saraswati K, Phanichkrivalkosil M, Day NPJ, Blacksell SD. The validity of diagnostic cut-offs for commercial and in-house scrub typhus IgM and IgG ELISAs: A review of the evidence. PLoS Negl Trop Dis. 2019;13(2):e0007158.
  15. Nandakumar V, Profaizer T, Lozier BK, Elgort MG, Larragoite ET, Williams E, et al. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays. Arch Pathol Lab Med. 2021;145(10):1212-20.
  16. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020;58(11).
  17. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. Nature. 2020.
  18. Gharbharan A, Jordans CCE, Geurtsvankessel C, den Hollander JG, Karim F, Mollema FPN, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. 2020.
  19. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538).
  20. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020.
  1. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv. 2021.
  2. Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J Clin Microbiol. 2021;59(4):e02438-20.
  3. Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front Immunol. 2020;11:610688.
  4. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, et al. Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. J Infect Dis. 2020;222(8):1280-8.
  5. Chen SY, Lee YL, Lin YC, Lee NY, Liao CH, Hung YP, et al. Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020;9(1):2157-68.
  6. Yassine HM, Al-Jighefee H, Al-Sadeq DW, Dargham SR, Younes SN, Shurrab F, et al. Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies. Int J Infect Dis. 2021;102:181-7.
  7. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650-5.
  8. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun. 2005;333(1):186-93.
آمار
تعداد مشاهده مقاله: 1,769
تعداد دریافت فایل اصل مقاله: 571


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب